A meta-analysis of clinical trials comparing milnacipran, a serotonin–norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder
- 1 January 2007
- journal article
- clinical trial
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 17 (1) , 32-36
- https://doi.org/10.1016/j.euroneuro.2006.05.001
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed OutpatientsThe Journal of Clinical Psychiatry, 2002
- Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamineInternational Clinical Psychopharmacology, 2001
- Sertraline Versus Paroxetine in Major Depression: Clinical Outcome After Six Months of Continuous TherapyJournal of Clinical Psychopharmacology, 2000
- A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practiceInternational Clinical Psychopharmacology, 1997
- DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSIONPsychiatric Clinics of North America, 1996
- Controlled comparison of milnacipran and fluoxetine in major depressionPsychopharmacology, 1994
- Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depressionInternational Clinical Psychopharmacology, 1993
- Interest of a loading dose of milnacipran in endogenous depressive inpatients: Comparison with the standard regimen and with fluvoxamineEuropean Neuropsychopharmacology, 1991
- Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter studyJournal of Affective Disorders, 1990
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986